Citations

Mayo Clinic

Showing 10 of 108551 citations.

Rituximab or cyclosporine A for the treatment of membranous nephropathy: economic evaluation of the MENTOR trial
So, Helen , Fervenza, Fernando C. , Cattran, Daniel C., Barbour, Sean J. , Investigators, MENTOR Study, Cattran, D C, Appel, Gerald B., Gipson, D, Erickson, Stephen B., Radhakrishnan, Jay, Bomback, A.S., Hogan, Jonathan, Arora, Neha , Nargund, Preeti, Alvarado, Anthony, Hebert, Lee A., Aslam, Nabeel , Porter, Ivan E. , Gipson, Patrick E., Plattner, Brandon L. , Gipson, D, Mariani, Laura , Garg, Pranay, Jefferson, J. Ashley , Nelson, Peter J. , Yarlagadda, Sri G. , Simon, James F. , Gebreselassie, Surafel , Blumenthal, Stanley A., Thomas, L, Cohen, Irvin M., Keddis, Mira T. , Sussman, Andrew L. , Thajudeen, Bijin , Fülöp, Tibor , Craici, Iasmina , Wagner, Steven J., DREISBACH, A, Monga, D., Green, D, Nayer, Ali, Thomas, D. B., Cattran, D C, Reich, Heather N. , Barbour, S. Lee , Philibert, D., Mac‐Way, Fabrice , Desmeules, Simon, Ankawi, Ghada , Sethi, Sanjeev , Ávila-Casado, Carmen , Beanlands, Heather , Fervenza, Fernando C , Kadatz, Matthew , Klarenbach, Scott W , Investigators, MENTOR Study, Cattran, D C, Gipson, D, Kretzler, Matthias , Rovin, Brad H. , Lieske, John C. , Leung, Nelson , Canetta, Pietro A. , Ahn, W, Lafayette, Richard , Arora, N, Parikh, Samir M. , Plattner, B, Gipson, D, Rao, P, Sedor, John R. , O'Toole, J, McCarthy, E, Jain, Namrata Gargee , Rizk, D, Blumenthal, S, Beara‐Lasić, Lada , Zhdanova, Olga A. , Thomas, L, Sussman, A, Juncos, Luis A. , Fulop, T, Monga, D, Mattiazzi, Adela D. , Thomas, D, Barisoni, Laura , Li, T, Vijayan, Anitha , Cattran, D C, Hladunewich, Michelle , Barbour, S, Levin, Adeera , Philibert, D

Nephrology Dialysis Transplantation | April 13, 2024 | Volume: 39 | Issue: 12 | Pages: 2058-2066

10.1093/ndt/gfae084 | PMID 38621719 Get It

ABSTRACT Background and hypothesis The MENTOR trial (MEmbranous Nephropathy Trial Of Rituximab) showed that rituximab was noninferior to cyclosporine in inducing complete or partial remission of proteinuria and was superior in maintaining proteinuria remission. However, the cost of rituximab may prohibit first-line use for some patients and health-care payers. Methods A Markov model was used to determine the incremental cost-effectiveness ratio (ICER) of rituximab compared with cyclosporine for the treatment membranous nephropathy from the perspective of a health-care payer with a lifetime time horizon. The model was informed by data from the MENTOR trial where possible; additional parameters including cost and utility inputs were obtained from the literature. Sensitivity analyses were performed to evaluate the impact of reduced-cost biosimilar rituximab. Results Rituximab for the treatment of membranous nephropathy was cost effective (assuming a willingness-to-pay threshold of $50 000 per quality-adjusted life year (QALY) gained; in $US 2021) compared with cyclosporine, with an ICER of $8373/QALY over a lifetime time horizon. The incremental cost of rituximab therapy was $28 007 with an additional 3.34 QALYs compared with cyclosporine. Lower cost of rituximab biosimilars resulted in a more favorable ICER, and in some cases resulted in rituximab being dominant (lower cost and great benefit) compared to cyclosporine. Conclusions Despite the greater cost of rituximab, it may be a cost-effective option for the treatment of membranous nephropathy when compared with cyclosporine. The cost-effectiveness of rituximab is further improved with the use of less expensive biosimilars.
High‐risk multiple myeloma: Redefining genetic, clinical, and functional high‐risk disease in the era of molecular medicine and immunotherapy
Kumar, Shaji , Rees, Matthew James , Kumar, Shaji K , Rees, Matthew J.

American Journal of Hematology | April 13, 2024 | Volume: 99 | Issue: 8 | Pages: 1560-1575

10.1002/ajh.27327 | PMID 38613829 Get It

Abstract Multiple myeloma (MM) exhibits significant heterogeneity in its presentation, genetics, and treatment response. Despite therapeutic advances, some patients continue to relapse early (ER, <18‐months) and rapidly cycle through therapies. Myriad prognostic factors have been identified and incorporated into risk stratification models; however, these produce discordant, often three‐tiered outputs that fail to identify many patients destined for ER. Treatment strategies are increasingly focused on disease biology and trials enriched for high‐risk (HR)MM, but consensus on the minimum required testing and a succinct, specific, and clinically meaningful definition for HRMM remains elusive. We review the risk‐factors, definitions, and future directions for HRMM.
Liposomal Phenylephrine Nanoparticles Enhance the Antitumor Activity of Intratumoral Chemotherapy in a Preclinical Model of Melanoma
Gabriel, Emmanuel , Bahr, Deborah, Rachamala, Hari Krishnareddy, Madamsetty, Vijay Sagar , Shreeder, Barath , Escobedo, A., Rachamalla, Hari Krishnareddy , Gabriel, Emmanuel M , Madamsetty, Vijay S , Escobedo, Amber L, Mukhopadhyay, Debabrata , Rachamala, Hari Krishnareddy , Bagaria, Sanjay P. , Escobedo, Amber L., Reid, Joel M. , Mukhopadhyay, Debabrata

ACS Biomaterials Science & Engineering | April 13, 2024 | Volume: 10 | Issue: 5 | Pages: 3412-3424

10.1021/acsbiomaterials.4c00078 | PMID 38613483 Get It

Letter re: Is a Multi-Modal Approach Needed to Enhance Thromboprophylaxis Prescribing in Obese Patients?
Shiue, Harn , Reynolds, Jenna , Shiue, Harn J

Journal of Pharmacy Practice | April 13, 2024 | Volume: 37 | Issue: 6 | Pages: 1235-1236

10.1177/08971900241247641 | PMID 38613469 Get It

Hypertrophic cardiomyopathy detection with artificial intelligence electrocardiography in international cohorts: an external validation study
Siontis, Konstantinos C. , Wieczorek, Mikolaj A. , Maanja, Maren , Hodge, David O. , Kim, Hyung‐Kwan , Lee, Heesun , Lim, Jaehyun , Ariga, Rina, Mahmod, Masliza , Ackerman, Michael J. , Friedman, Paul A. , Raman, Betty , Mahmod, Masliza , Watkins, Hugh , Neubauer, Stefan , Windecker, Stephan , Ackerman, Michael J , Friedman, Paul A , Kim, Hyung-Kwan , Lee, Hyun‐Jung , Park, Chan Soon , Watkins, Hugh , Windecker, Stephan , Siontis, George C.M. , Gersh, Bernard J. , Attia, Zachi I. , Noseworthy, Peter A.

European Heart Journal - Digital Health | April 13, 2024 | Volume: 5 | Issue: 4 | Pages: 416-426

10.1093/ehjdh/ztae029 | PMID 39081936 Get It

Abstract Aims Recently, deep learning artificial intelligence (AI) models have been trained to detect cardiovascular conditions, including hypertrophic cardiomyopathy (HCM), from the 12-lead electrocardiogram (ECG). In this external validation study, we sought to assess the performance of an AI-ECG algorithm for detecting HCM in diverse international cohorts. Methods and results A convolutional neural network-based AI-ECG algorithm was developed previously in a single-centre North American HCM cohort (Mayo Clinic). This algorithm was applied to the raw 12-lead ECG data of patients with HCM and non-HCM controls from three external cohorts (Bern, Switzerland; Oxford, UK; and Seoul, South Korea). The algorithm’s ability to distinguish HCM vs. non-HCM status from the ECG alone was examined. A total of 773 patients with HCM and 3867 non-HCM controls were included across three sites in the merged external validation cohort. The HCM study sample comprised 54.6% East Asian, 43.2% White, and 2.2% Black patients. Median AI-ECG probabilities of HCM were 85% for patients with HCM and 0.3% for controls (P &lt; 0.001). Overall, the AI-ECG algorithm had an area under the receiver operating characteristic curve (AUC) of 0.922 [95% confidence interval (CI) 0.910–0.934], with diagnostic accuracy 86.9%, sensitivity 82.8%, and specificity 87.7% for HCM detection. In age- and sex-matched analysis (case–control ratio 1:2), the AUC was 0.921 (95% CI 0.909–0.934) with accuracy 88.5%, sensitivity 82.8%, and specificity 90.4%. Conclusion The AI-ECG algorithm determined HCM status from the 12-lead ECG with high accuracy in diverse international cohorts, providing evidence for external validity. The value of this algorithm in improving HCM detection in clinical practice and screening settings requires prospective evaluation.
Non‐canonical IKB kinases regulate YAP/TAZ and pathological vascular remodeling behaviors in pulmonary artery smooth muscle cells
Aravamudhan, Aja, Dieffenbach, Paul B., Choi, Kyoung Moo , Link, Patrick A. , Meridew, Jeffrey A., Haak, Andrew J. , Fredenburgh, Laura E. , Tschumperlin, Daniel J. , Link, Patrick A

Physiological Reports | April 13, 2024 | Volume: 12 | Issue: 7 | Pages: No page available

10.14814/phy2.15999 | PMID 38610069 Get It

AbstractPulmonary arterial hypertension (PAH) causes pulmonary vascular remodeling, increasing pulmonary vascular resistance (PVR) and leading to right heart failure and death. Matrix stiffening early in the disease promotes remodeling in pulmonary artery smooth muscle cells (PASMCs), contributing to PAH pathogenesis. Our research identified YAP and TAZ as key drivers of the mechanobiological feedback loop in PASMCs, suggesting targeting them could mitigate remodeling. However, YAP/TAZ are ubiquitously expressed and carry out diverse functions, necessitating a cell‐specific approach. Our previous work demonstrated that targeting non‐canonical IKB kinase TBK1 reduced YAP/TAZ activation in human lung fibroblasts. Here, we investigate non‐canonical IKB kinases TBK1 and IKKε in pulmonary hypertension (PH) and their potential to modulate PASMC pathogenic remodeling by regulating YAP/TAZ. We show that TBK1 and IKKε are activated in PASMCs in a rat PH model. Inflammatory cytokines, elevated in PAH, activate these kinases in human PASMCs. Inhibiting TBK1/IKKε expression/activity significantly reduces PAH‐associated PASMC remodeling, with longer‐lasting effects on YAP/TAZ than treprostinil, an approved PAH therapy. These results show that non‐canonical IKB kinases regulate YAP/TAZ in PASMCs and may offer a novel approach for reducing vascular remodeling in PAH.
Hemoadsorption: consensus report of the 30th Acute Disease Quality Initiative workgroup
Bellomo, Rinaldo , Ankawi, Ghada , Baldwin, Ian , Bottari, Gabriella , Clark, William R. , Rosa, Silvia De , Fuhrman, Dana Y. , Goldstein, Stuart L. , Gómez, Hernando , Joannidis, Michael , Lorenzin, Anna , Murugan, Ragi, Premužić, Vedran , Prowle, John R. , Rimmelé, Thomas , Rosner, Mitch, Schneider, Antoine , Zarbock, Alexander , Bagshaw, Sean M. , Basu, Rajit K. , Cantaluppi, Vincenzo , Forni, Lui G. , Husain‐Syed, Faeq , Kashani, Kianoush , Mehta, Ravindra L. , Murray, Patrick T. , Ostermann, Marlies , Pannu, Neesh , Reis, Thiago , Ronco, Claudio , Rosner, Mitchell H. , See, Emily , Soranno, Danielle E. , Villa, Gianluca , Whaley‐Connell, Adam T.

Nephrology Dialysis Transplantation | April 13, 2024 | Volume: 39 | Issue: 12 | Pages: 1945-1964

10.1093/ndt/gfae089 | PMID 38621759 Get It

ABSTRACT Adsorption-based extracorporeal therapies have been subject to technical developments and clinical application for close to five decades. More recently, new technological developments in membrane and sorbent manipulation have made it possible to deliver more biocompatible extracorporeal adsorption therapies to patients with a variety of conditions. There are several key rationales based on physicochemical principles and clinical considerations that justify the application and investigation of such therapies as evidenced by multiple ex vivo, experimental and clinical observations. Accordingly, unspecific adsorptive extracorporeal therapies have now been applied to the treatment of a wide array of conditions from poisoning to drug overdoses, to inflammatory states and sepsis, and acute or chronic liver and kidney failure. In response to the rapidly expanding knowledge base and increased clinical evidence, we convened an Acute Disease Quality Initiative consensus conference dedicated to such treatment. The data show that hemoadsorption has clinically acceptable short-term biocompatibility and safety, technical feasibility and experimental demonstration of specified target molecule removal. Pilot studies demonstrate potentially beneficial effects on physiology and larger studies of endotoxin-based hemoadsorption have identified possible target phenotypes for larger randomized controlled trials. Moreover, in a variety of endogenous and exogenous intoxications, removal of target molecules has been confirmed in vivo. However, some studies have raised concerns about harm, or failed to deliver benefits. Thus, despite many achievements, modern hemoadsorption remains a novel and experimental intervention with limited data, and a large research agenda.
Radiology-pathology correlation: Giant tumefactive perivascular spaces
Benson, John C. , Trejo‐Lopez, Jorge , Cormier, Jason L, Mark, Ian T. , Madhavan, Ajay A. , Rydberg, Charlotte H. , Eckel, Laurence J. , Trejo-Lopez, Jorge A, Mark, Ian , Madhavan, Ajay A , Kotsenas, Amy L. , Johnson, Derek R , Benson, John , Parney, Ian F. , Luetmer, Patrick H. , Johnson, Derek R.

The Neuroradiology Journal | April 13, 2024 | Volume: 38 | Issue: 2 | Pages: 233-237

10.1177/19714009241247459 | PMID 38613202 Get It

Dilated perivascular spaces (PVSs) are common and easily recognized on imaging. However, rarer giant tumefactive PVSs (GTPVSs) can have unusual multilocular cystic configurations, and are often confused for other pathologic entities, including neoplasms, cystic infarctions, and neuroepithelial cysts. Because GTPVSs are scarcely encountered and even more infrequently operated upon, many radiologists are unaware of the imaging and pathologic features of these lesions. Here, a case of a resected GTPVS is presented, highlighting both its radiologic and histologic characteristics, and discussing how such lesions can be differentiated from their closest mimickers on imaging.
Machine learning for enhanced prognostication: predicting 30-day outcomes following posterior fossa decompression surgery for Chiari malformation type I in a pediatric cohort
Elmi‐Terander, Adrian , Ahn, Edward S. , Bydon, Mohamad , Elmi-Terander, Adrian , El-Hajj, Victor Gabriel , El-Hajj, Victor Gabriel , Ghaith, Abdul Karim , Daniels, David J.

Journal of Neurosurgery: Pediatrics | April 13, 2024 | Volume: 34 | Issue: 1 | Pages: 57-65

10.3171/2024.2.peds23523 | PMID 38608292 Get It

OBJECTIVE Chiari malformation type I (CM-I) is a congenital disorder occurring in 0.1% of the population. In symptomatic cases, surgery with posterior fossa decompression (PFD) is the treatment of choice. Surgery is, however, associated with peri- and postoperative complications that may require readmission or renewed surgical intervention. Given the associated financial costs and the impact on patients’ well-being, there is a need for predictive tools that can assess the likelihood of such adverse events. The aim of this study was therefore to leverage machine learning algorithms to develop a predictive model for 30-day readmissions and reoperations after PFD in pediatric patients with CM-I. METHODS This was a retrospective study based on data from the National Surgical Quality Improvement Program–Pediatric database. Eligible patients were those undergoing PFD (Current Procedural Terminology code 61343) for CM-I between 2012 and 2021. Patients undergoing surgery for tumors or vascular lesions were excluded. Unplanned 30-day readmission and unplanned 30-day reoperation were the main study outcomes. Additional outcome data considered included the length of hospital stay, 30-day complications, discharge disposition, and 30-day mortality. Training and testing samples were randomly generated (80:20) to study the 30-day readmission and reoperation using logistic regression, decision tree, random forest (RF), K-nearest neighbors, and Gaussian naive Bayes algorithms. RESULTS A total of 7106 pediatric patients undergoing PFD were included. The median age was 9.2 years (IQR 4.7, 14.2 years). Most of the patients were female (56%). The 30-day readmission and reoperation rates were 7.5% and 3.4%, respectively. Headaches (32%) and wound-related complications (30%) were the most common reasons for 30-day readmission, while wound revisions and evacuation of fluid or blood (62%), followed by CSF diversion-related procedures (28%), were the most common reasons for 30-day reoperation. RF classifiers had the highest predictive accuracy for both 30-day readmissions (area under the curve [AUC] 0.960) and reoperations (AUC 0.990) compared with the other models. On feature importance analysis, sex, developmental delay, ethnicity, respiratory disease, premature birth, hydrocephalus, and congenital/genetic anomaly were some of the variables contributing the most to both RF models. CONCLUSIONS Using a large-scale nationwide dataset, machine learning models for the prediction of both 30-day readmissions and reoperations were developed and achieved high accuracy. This highlights the utility of machine learning in risk stratification and surgical decision-making for pediatric CM-I.
Letter to the Editor. Headache relief after anterior decompression: is there really an association?
Gujral, Jaskeerat , Gandhi, Om H. , Sommer, Fabian , Navarro-Ramírez, Rodrigo , Gandhi, Om , Bielecki, Mateusz , Gadjradj, Pravesh S.

Journal of Neurosurgery: Spine | April 13, 2024 | Volume: 41 | Issue: 1 | Pages: 146-147

10.3171/2024.1.spine2428 | PMID 38608291 Get It